UROLOGY MAIN SITE GEN. ADULT UROLOGY UROLOGIC ONCOLOGY MALE UROLOGY TRANSPLANT PROGRAM
PELVIC MEDICINE, INCONTINENCE & RECONST. SURGERY PEDIATRIC UROLOGY MIN. INVASIVE SURGERY
About Us
Our History
Faculty Information
Conditions
Innovations & Technology
Research & Clinical
Trials
For Patients
Academic Information
News & Events
Useful Links
Department Directory
Facilities & Directions
How You Can Help
Contact Us
Department of
Urology Intranet

Gang Zeng, PhD
a Curriculum Vitae

Gang Zeng, PhD
Assistant Professor of Urology and Jonsson Comprehensive Cancer Center, David Geffen School of Medicine at UCLA

Location: 12-956 Factor
 
Phone: 310-794-7635
Educational Background
Undergraduate: B.S., Cell Biology and Genetics, Peking (Beijing) University, Beijing, China, July 1991.
Medical School: Ph.D., Biochemistry, Virginia Polytechnic Institute and State University (Virginia Tech), Blacksburg, Virginia, February 1996.
Board
Certifications
& Fellowships:		 Fellowship, Surgery Branch, National Cancer Institute, National Institutes of Health, June 2000.

Professional Memberships
Member, American Association for the Advancement of Science (AAAS).
Member, American Association of Immunologists (AAI).
Member, American Association for Cancer Research (AACR).
Member, Society for Biological Therapy (SBT).
Member, Chinese Biopharmaceutical Association (CBA).

Academic & Medical Staff Appointments
Assistant Professor (September 2002-), Department of Urology and Jonsson Cancer Center, David Geffen School of Medicine at UCLA, Los Angeles, CA.
Director of Research (September 2002-), UCLA Kidney Cancer Program.

Research Fellow (June 2000 – September 2002)
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Postdoctoral Fellow (July 1997 – June 2000)
Surgery Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD.
Postdoctoral Fellow (March 1996 - June 1997)
Research Institute for Genetic & Human Therapy (RIGHT), Georgetown University Medical Center, Washington, D.C.
Undergraduate Researcher (December 1990 – July 1991)
Department of Human Genetics, Chinese Ministry of Public Security, Beijing, China

Research & Clinical Interests
urologic oncology, tumor immunology, cancer vaccine development..

Awards & Honors
Associate Membership, National Cancer Institute Early Detection Research Network (EDRN).
Reviewer, Innovative Technologies for Molecular Analysis of Cancer (IMAT) Program, National Cancer Institute, March 2007.
Lab2Market Award, UCLA office of research administration, June 2006.
Reviewer, Prostate Cancer Immunological Science Panel of the Congressionally Directed Medical Research Program, June 2006.
Stein Oppenheimer Award, David Geffen School of Medicine at UCLA, Feb. 2004.
Certificate of Achievement, Division of Clinical Sciences, National Cancer Institute, May 2000.
Blanche Wu Memorial Scholarship, Virginia Tech, Blacksburg, VA, 1995.
Honored Undergraduate Thesis, Beijing University, China, 1991.


  Additional Information


INVITED LECTURES


1. 2004 Annual Meeting of the American Urological Association, San Francisco, CA, May 2004
2. UCLA lung cancer SPORE research seminar, Los Angeles, CA, Nov 2003.
3. UCLA Department of Urology Grand Round research seminar, Los Angeles, CA, March 2003.
4. Jonsson Comprehensive Cancer Center Genito-urinary Cancer Research seminar, UCLA, Los Angeles, CA, February 2003.
5. Gene Medicine Research Seminar, UCLA medical center, Los Angeles, CA, January 2003.
6. Maxine Dunitz Neurosurgical Institute, Ceders-Sinai Medical Center, Los Angeles, CA, December 2002.
7. MedCell Biologics, Inc., San Diego, CA, May 2002.
8. Tumor-Associated Antigens and Immunotherapy of Cancer Symposium, American Association of Immunologists Annual Meetings, Experimental Biology 2002, New Orleans, LA, April 2002.
9. Function of Professional Antigen Presenting Cells Symposium, American Association of Immunologists Annual Meetings, Experimental Biology 2002, New Orleans, LA, April 2002.
10. Department of Biologics, Celera Genomics, Inc., Rockville, MD, January 2002.
11. Chinese Association of Scientists and Engineers in the USA (CAST) Annual Conference on Science, Technology, and Business Opportunities, Newark, NJ, December 2001.
12. National Cancer Institute Molecular Targets Program Retreat, Leesburg, VA, November 2001.
13. Department of Surgery, University of Maryland School of Medicine, Baltimore, MD, July 2001.
14. Department of Biologics, Celera Genomics, Inc., Rockville, MD, July 2001.
15. The Philips Institute, Medical College of Virginia at the Virginia Commonwealth University, Richmond, VA, May 2001.
16. Maxine Dunitz Neurosurgical Institute, Ceders-Sinai Medical Center, Los Angeles, CA, March 2001. 
17. Epimmune Inc., San Diego, CA, March 2001.
18. 15th Annual Scientific Meeting of the Society for Biological Therapy, Seattle, WA, October 2000.
19. Vaccinex, LP, Rochester, NY, July 2000.
20. Chiron Corp., Emerville, CA, June 2000.

BIBLIOGRAPHY

      Research papers:

  1. Zeng, G., Ye, S., and Larson, T. J. (1996) “Repressor for the sn-glycerol 3-phosphate regulon of Escherichia coli K-12, primary structure and identification of the DNA-binding domain.” J. Bacteriol. 178(24): 7080-7089.
  2. Zeng, G., and Larson, T. J. (1996) “Use of an engineered thrombin cleavage site for the determination of translational reading frames.” Bio/techniques 21(5): 822-824.
  3. Wang, R.F., Wang, X., Johnston, S.L., Zeng, G., Robbins, P.F., and Rosenberg, S.A. (1998) “Development of a retrovirus-based complementary DNA expression system for the cloning of tumor antigens.” Cancer Res. 58(16): 3519-3525.
  4. Zeng, G*. (1998) “Sticky-end PCR: a new method for subcloning.” Bio/techniques 25(2): 206-8.   (*corresponding author).
  5. Wang, R.F., Johnston, S.L., Zeng, G., Schwartzentruber, D.J., and Rosenberg, S.A. (1998) “A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames.” J. Immunol. 161(7): 3596-3606.
  6. Ray, W.K., Zeng, G., Potters, M.B., Mansuri, A.M., and Larson, T.J. (2000) “Characterization of a 12-kDa rhodanese encoded by glpE of Escherichia coli and its interaction with thioredoxin” J. Bacteriol. 182(8):2277-2284.
  7. J. Lisziewicz, G. Zeng, C. Grata, J.N. Weinstein, and F. Lori (2000) “Combination Gene Therapy: Synergistic Inhibition of Human Immunodeficiency Virus Tat and Rev Functions by a Single RNA Molecule.” Human Gene Therapy. 11(6):807-816.
  8. Zeng, G., Touloukian, C.E., Wang, X., Restifo, N.P., Rosenberg, S.A., and Wang, R.F. (2000) “Identification of CD4+ T cell epitopes from NY-ESO-1 presented by HLA-DR molecules.” J. Immunol. 165(2):1153-1159.
  9. Zeng, G., Wang, X., Robbins, P.F., Rosenberg, S.A., and Wang, R.F. (2001) “ CD4+ T cell recognition of MHC class II-restricted epitopes from NY-ESO-1 presented by a prevalent HLA DP4 allele: Association with NY-ESO-1 antibody production.” Proc. Natl. Acad. Sci. USA. 98(7): 3964-3969.   (peer-reviewed track II article).
  10. Zeng, G*. (2001) “Review: MHC class II-restricted tumor antigens recognized by CD4+ T cells: New opportunities for cancer vaccine design.” J. Immunother.  24(3): 195-204.  (*corresponding author).
  11. Ying, H., Zeng, G., and Black, K. (2001) “Innovative strategies for cancer vaccine development based on the identification of tumor associated antigens.” BioDrugs 15:819-31.
  12. Wang, H.Y., Fu, T., Wang, G., Zeng, G., Perry-Lalley, D., Yang, J.C., Restifo, N.P., Hwu, P., and Wang, R-F. (2002) “Induction of CD4+ T cell-dependent antitumor immunity by TAT-mediated tumor antigen delivery into dendritic cells.”  J. Clin. Invest. 109:1463-1470.
  13. Zeng, G*., Li, Y., El-Gamil, M., Sidney, J., Sette A., Wang, R-F., Rosenberg, S.A., and Robbins, P.F. (2002) “Generation of NY-ESO-1 specific CD4+ and CD8+ T cells by a single peptide with dual MHC class I and class II specificities: A new strategy for vaccine design.” Cancer Res.   62(13):3630-3635 (*corresponding author).
  14. Wang R.F., Zeng, G., Johnston SL., Voo K., Ying, H. (2002) “T cell-mediated immune responses in melanoma: implications for immunotherapy.” Crit. Rev. Oncol.Hematol. 43:1-11.
  15. Robbins, P.F., El-Gamil, M., Li, Y. F., Zeng, G., Dudley, M., and Rosenberg, S.A. (2002) “Recognition of multiple HLA class II restricted melanocyte differentiation antigens by TIL from a patient with melanoma.”  J. Immunol. 169:6036-6047.
  16. Pantuck, A.J., Zeng, G., Belldegrun, A.S., and Figlin, R.A. (2003) “Pathobiology, prognosis and targeted therapy for renal cell carcinoma: Exploiting the hypoxia-induced pathway.”  Clin. Cancer Res.  9(13):4641-52.
  17. Liu, G.T., Ying, H., Zeng, G., Wheeler, C., Black, K.L., and Yu, J.S. (2004) “HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells.”  Cancer Res.  64(14):4980-6. 
  18. Liu, G.T., Yu, J.S., Zeng, G, Yin, D., Xie, D., Black, K.L., Ying, H. (2004) “AIM-2: A novel tumor antigen is expressed and presented by human glioma cells.” J. Immunother.  27(3):220-226.
  19. Mukouyama, H., Janzen, NK, Hernandez, J.M., Lam, J.S., Caliliw, R., Wang, A.Y., Figlin, R.A., Belldegrun, AS., and Zeng, G.* (2004) “Generation of kidney cancer specific anti-tumor immune responses using peripheral blood monocytes transduced with a recombinant adenovirus encoding Carbonic Anhydrase 9.” Clin. Cancer Res.  10(4):1421-1429. (*Corresponding author).
  20. Zeng, G.*, Aldridge, M.E., Wang, Y., Pantuck, A.J., Wang, A.Y., Liu, Y., Han Y., Yuan, Y-H, Robbins, P.F., Dubinett, S.M., and Belldegrun, A.S. (2005) “A dominant B cell epitope from NY-ESO-1 recognized by sera from a wide spectrum of cancer patients: Implications as a potential cancer biomarker.” Intl. J. Cancer. 114, 268-273. (*Corresponding author).  This article is featured on the “Selected Abstracts” in the September 2006 issue of College of American Pathologists Today”
  21. Baratelli, F., Lin, Y., Zhu, L., Yang, S-C, Heuz-Vourc'h, N., Zeng, G., Reckamp, K., Dohadwala, K., Sharma, S., and Dubinett, S.M. “PGE2 induces FOXP3 gene expression and T regulatory cell function in human CD4+ T cells” (2005) J. Immunol. 175(3):1483-90.
  22. Z. S. Guo, J.A. Hong, K.R. Irvine, G. A. Chen, P.J. Spiess, Y. Liu, G. Zeng, J.R. Wunderlich, D.M. Nguyen, N.P. Restifo, and D.S. Schrump “De novo induction of a cancer/testis antigen by 5-aza-2’-deoxycytidine augments adoptive immunotherapy in a murine tumor model.” (2006) Cancer Res. 66(2):1105-13.
  23. Zeng, G.*, Voo, K., Mu, J-B., Zhou, J., Su, X-Z., and Wang, R.F. “CD4+ T-cell response to mitochondrial cytochrome b in human melanoma” (2006) Cancer Res. 66:5919-5926 (*Equal-contribution first author).
  24. Lam JS, Seligson DB, Yu H, Li A, Eeva M, Pantuck AJ, Zeng G, Horvath S, Belldegrun AS. “Flap endonuclease 1 is overexpressed in prostate cancer and is associated with a high Gleason score.” BJU Int. (2006) 98(2):445-51. 
  25. Shvarts, O, Janzen, N., Lam, J.S., Leppert, J.T., Figlin, R.J., Belldegrun, A.S., and Zeng, G*. “RENCA/CA IX: A murine model of a CA IX expressing renal cell carcinoma”. (2006) Urol. 68:1132-1138 (*Corresponding author).
  26. Zeng, G.*, Aldridge ME, Tian X, Seiler D, Zhang X, Jin Y, Rao J, Li W, Chen D, Langford MP, Duggan C, Belldegrun AS, Dubinett SM (2006) “Dendritic cell surface calreticulin is a receptor for NY-ESO-1: Direct interactions between tumor-associated antigen and the innate immune system.” J. Immunol. 177(6):3582-3589 (*Corresponding author).

Patents:

1.      “MHC class II restricted CD4+ T cell epitopes from NY-ESO-1” by G. Zeng, R.F. Wang, and S.A. Rosenberg, U.S. patent 60/237,107 and international patent PCT/US01/02765.  This patent was licensed to Altor Biosciences Corporation in 2006.

2.      “Dominant B Cell Epitopes and Methods of Making and Using Thereof” by Zeng, G., U.S. patent: 60/572,474 and international patent PCT/US2005/017589.  This patent received the Lab2Market Award from a venture capital fund in June 2006.

3.      “Controllable attachment of peptides and proteins by electrochemical methods for biological sensing array” by G. Zeng and Y. Chen, US provisional patent. 

4.      “Methods for the functional isolation of prostate cancer stem cells” by G. Zeng, A.S. Belldegrun, US provisional patent. 

 

Abstracts: more than 50, not included.

 

Manuscript submitted:

D. Seiler, G. Liu, M.E. Aldridge, S. Wang, X. Tian, A. Oudes, A.Y. Liu, J. Rao, A.S. Belldegrun, G. Zeng* “Isolation of a clonal prostate cancer-initiating cell with self-renewal capacity and phenotypic plasticity.” (2007) Manuscript submitted to Cancer Res. (*corresponding author).